Pertuzumab, first approved by the FDA in 2012, binds to ECD II of the HER2 receptor and can act synergically with trastuzumab by preventing the heterodimerization of HER2 with other HER receptors, resulting in further inhibition of downstream tumor signaling [23]. Here, ERBB2 is linked to neoplasm.